MiR203 mediates subversion of stem cell properties during mammary epithelial differentiation via repression of δnP63α and promotes mesenchymal-to-epithelial transition

Cell Death and Disease

Volumn 4, Issue 2, 2013, Pages

  DeCastro, A J ^a   Dunphy, K A ^b   Hutchinson, J ^a   Balboni, A L ^a   Cherukuri, P ^a   Jerry, D J ^b   DiRenzo, J ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Mammary stem cells; Mesenchymal to epithelial transition (MET); MicroRNA; MiR203; P63; Zeb1

Indexed keywords

MICRORNA; MICRORNA 203; PROTEIN; PROTEIN DELTANP63ALPHA; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BREAST EPITHELIUM; CANCER STEM CELL; CELL CULTURE; CELL DIFFERENTIATION; CELL LEVEL; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; CLONOGENESIS; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE REPRESSION; HUMAN; HUMAN CELL; MAMMARY STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; EPITHELIAL-MESENCHYMAL TRANSITION; G1 PHASE CELL CYCLE CHECKPOINTS; HOMEODOMAIN PROTEINS; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY GLANDS, HUMAN; MCF-7 CELLS; MICE; MICRORNAS; NEOPLASTIC STEM CELLS; PROTEIN ISOFORMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; STEM CELLS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

MURINAE;

EID: 84875968686     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.37     Document Type: Article

References (54)

1. Hennighausen L, Robinson GW. Think globally, act locally: the making of a mouse mammary gland. Genes Dev 1998; 12: 449-455.
2. Visvader JE. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev 2009; 23: 2563-2577.
3. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML et al. Generation of a functional mammary gland from a single stem cell. Nature 2006; 439: 84-88.
4. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D et al. Purification and unique properties of mammary epithelial stem cells. Nature 2006; 439: 993-997.
5. Eirew P, Stingl J, Raouf A, Turashvili G, Aparicio S, Emerman JT et al. A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nat Med 2008; 14: 1384-1389.
6. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009; 15: 907-913.
7. DiRenzo J, Signoretti S, Nakamura N, Rivera-Gonzalez R, Sellers W, Loda M et al. Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. Cancer Res 2002; 62: 89-98.
8. Li H, Cherukuri P, Li N, Cowling V, Spinella M, Cole M et al. Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res 2007; 67: 501-510.
9. Li N, Singh S, Cherukuri P, Li H, Yuan Z, Ellisen LW et al. Reciprocal intraepithelial interactions between TP63 and hedgehog signaling regulate quiescence and activation of progenitor elaboration by mammary stem cells. Stem Cells 2008; 26: 1253-1264.
10. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398: 708-713.
11. Senoo M, Pinto F, Crum CP, McKeon F. p63 is essential for the proliferative potential of stem cells in stratified epithelia. Cell 2007; 129: 523-536.
12. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398: 714-718.
13. Keyes WM, Pecoraro M, Aranda V, Vernersson-Lindahl E, Li W, Vogel H et al. DeltaNp63alpha is an oncogene that targets chromatin remodeler Lsh to drive skin stem cell proliferation and tumorigenesis. Cell Stem Cell 2011; 8: 164-176.
14. Jung MS, Yun J, Chae HD, Kim JM, Kim SC, Choi TS et al. p53 and its homologues, p63 and p73, induce a replicative senescence through inactivation of NF-Y transcription factor. Oncogene 2001; 20: 5818-5825.
15. Keyes WM, Wu Y, Vogel H, Guo X, Lowe SW, Mills AA. p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev 2005; 19: 1986-1999.
16. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007; 117: 1370-1380.
17. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006; 9: 45-56.
18. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
19. Ivey KN, Srivastava D. MicroRNAs as regulators of differentiation and cell fate decisions. Cell stem cell 2010; 7: 36-41.
20. Gangaraju VK, Lin H. MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell Biol 2009; 10: 116-125.
21. Lena AM, Shalom-Feuerstein R, Rivetti di Val Cervo P, Aberdam D, Knight RA, Melino G et al. miR-203 represses 'stemness' by repressing DeltaNp63. Cell Death Differ 2008; 15: 1187-1195.
22. Yi R, Poy MN, Stoffel M, Fuchs E. A skin microRNA promotes differentiation by repressing 'stemness'. Nature 2008; 452: 225-229.
23. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007; 67: 8699-8707.
24. Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P, Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer 2010; 126: 73-80.
25. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425-436.
26. Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010; 31: 766-776.
27. Saini S,Majid S, Yamamura S, Tabatabai L, Suh SO, Shahryari V et al. Regulatory role of mir- 203 in prostate cancer progression and metastasis. Clin Cancer Res 2011; 17: 5287-5298.
28. Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 2012; 18: 74-82.
29. Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M et al. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 2007; 26: 6979-6988.
30. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9: 582-589.
31. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
32. Blick T, Hugo H, Widodo E, Waltham M, Pinto C, Mani SA et al. Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia 2010; 15: 235-252.
33. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW et al. p53 regulates epithelialmesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 2011; 13: 317-323.
34. Mani SA, GuoW, LiaoMJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
35. Vaillant F, Asselin-Labat ML, Shackleton M, Forrest NC, Lindeman GJ, Visvader JE. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res 2008; 68: 7711-7717.
36. Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 2007; 9: 201-209.
37. Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 2006; 127: 1041-1055.
38. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A et al. The EMTactivator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009; 11: 1487-1495.
39. Borrelli S, Candi E, Hu B, Dolfini D, Ravo M, Grober OM et al. The p63 target HBP1 is required for skin differentiation and stratification. Cell Death Differ 2010; 17: 1896-1907.
40. Yao CJ, Works K, Romagnoli PA, Austin GE. Effects of overexpression of HBP1 upon growth and differentiation of leukemic myeloid cells. Leukemia 2005; 19: 1958-1968.
41. Danielson KG, Oborn CJ, Durban EM, Butel JS, Medina D. Epithelial mouse mammary cell line exhibiting normal morphogenesis in vivo and functional differentiation in vitro. Proc Natl Acad Sci USA 1984; 81: 3756-3760.
42. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003; 17: 1253-1270.
43. Al-Hajj M,Wicha MS, Benito-Hernandez A,Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
44. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007; 11: 259-273.
45. Nguyen DH, Oketch-Rabah HA, Illa-Bochaca I, Geyer FC, Reis-Filho JS, Mao JH et al. Radiation acts on the microenvironment to affect breast carcinogenesis by distinct mechanisms that decrease cancer latency and affect tumor type. Cancer Cell 2011; 19: 640-651.
46. Paulson KE, Rieger-Christ K, McDevitt MA, Kuperwasser C, Kim J, Unanue VE et al. Alterations of the HBP1 transcriptional repressor are associated with invasive breast cancer. Cancer Res 2007; 67: 6136-6145.
47. Escamilla-Powers JR, Daniel CJ, Farrell A, Taylor K, Zhang X, Byers S et al. The tumor suppressor protein HBP1 is a novel c-myc-binding protein that negatively regulates c-myc transcriptional activity. J Biol Chem 2010; 285: 4847-4858.
48. Sampson EM, Haque ZK, Ku MC, Tevosian SG, Albanese C, Pestell RG et al. Negative regulation of the Wnt-beta-catenin pathway by the transcriptional repressor HBP1. EMBO J 2001; 20: 4500-4511.
49. Aydogdu E, Katchy A, Tsouko E, Lin CY, Haldosen LA, Helguero L et al. MicroRNAregulated gene networks during mammary cell differentiation are associated with breast cancer. Carcinogenesis 2012; 33: 1502-1511.
50. Castilla MA, Moreno-Bueno G, Romero-Perez L, Van De Vijver K, Biscuola M, Lopez- Garcia MA et al. Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol 2011; 223: 72-80.
51. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-273.
52. Spaderna S, Schmalhofer O, Wahlbuhl M, Dimmler A, Bauer K, Sultan A et al. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 2008; 68: 537-544.
53. Baffa R, FassanM, Volinia S, O'Hara B, Liu CG, Palazzo JP et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 2009; 219: 214-221.
54. Li N, Li H, Cherukuri P, Farzan S, Harmes DC, DiRenzo J. TA-p63-gamma regulates expression of DeltaN-p63 in a manner that is sensitive to p53. Oncogene 2006; 25: 2349-2359.